AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05956925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group was asked to take their BP daily and rate their motivation level and communicate with the research assistant. Their level will trigger the appropriate behavioral change SMS prompt.
Description: The investigators showed participants how to use the Health Mate app, upload Withings BP cuff readings, upload historical data to the cloud, read trend lines in their record, rank their daily motivational level, and answer a brief short message service (SMS) question about whether the participants completed the behavioral change task encouraged by the daily message. A one-page instruction sheet with the research team's contact information was provided. Participants were instructed to take their BP daily, before their first meal and encouraged to avoid prior alcohol and caffeine intake as well as physical activity. The participants were instructed to rate their motivational level as low, moderate, or high via SMS when transmitting their BP value. Their level will trigger the appropriate behavioral change SMS prompt.
Study NCT02891980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26 Zaire Ebola Vaccine
Description: A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
Study NCT02891980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA Multi-Filo Ebola Vaccine
Description: A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
Study NCT05514431 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural
Description: Traditional epidural catheter placement
Study NCT05514431 — intervention group
Intervention type: PROCEDURE
Intervention: Dural Puncture Epidural (DPE) technique
Description: Epidural catheters placed via DPE technique
Study NCT05514431 — intervention group
Intervention type: PROCEDURE
Intervention: Combined Spinal-Epidural (CSE) technique
Description: Epidural catheters placed via CSE technique
Study NCT01863745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Nilotinib was administered daily as hard gelatin capsules for oral use. The starting dose of nilotinib was same as the last dose given in the parent nilotinib study. After this, the dose of nilotinib was based on the investigator's judgment. The total daily dose was up to 800 mg.
Study NCT00418145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megadose oral methylprednisolone
Description: 1400 mg qd/5 days
Study NCT00418145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylprednisolone
Description: 1000 mg/qd/5 days
Study NCT04038125 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ozurdex Drug Implant Product
Description: Intravitreal Ozurdex injection
Study NCT04033913 — intervention group
Intervention type: OTHER
Intervention: Self questionnaire
Description: Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
Study NCT04195412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS + upper limb rehabilitation
Description: Stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. Stimulation intensity will be 2 mA with current ramping up and down of 10 seconds each. The stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
Study NCT04195412 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + upper limb rehabilitation
Description: Sham stimulation will be applied for 20 minutes by a DC stimulator (NeuroConn, Germany). During each sham stimulation section, a pair of saline-soaked sponge electrodes (surface 24 cm²) will be placed over C3 and C4, according to the International 10-20 EEG system. The anode will be placed to the affected hemisphere, while the cathode will be positioned over the unaffected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off automatically after 30 seconds. The sham stimulation will be followed by 40 minutes of upper limb rehabilitation. Experimental sessions will be repeated five times per week to complete 10 sessions.
Study NCT04136301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative Video group
Description: Informative Video group before labor in nulliparous women
Study NCT02591303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress reactions measurement during stressful and neutral driving sessions
Description: Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
Study NCT00169260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational counseling
Description: behavioral motivational counselling
Study NCT00169260 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01406912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recreational Activity
Description: Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
Study NCT01406912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Gaming System Arm
Description: Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
Study NCT00989027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study NCT00989027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergonovine
Description: Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study NCT00989027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboprost
Description: Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study NCT00989027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Ergonovine
Description: Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study NCT00989027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin and Carboprost
Description: Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
Study NCT00744835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation procedure and/or cardioversion
Description: Ablation Frontiers Cardiac Ablation System
Study NCT04732585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy or Surgery
Description: Physiotherapy: Guidelines suggest a tailored and progressive exercise program to improve muscle strength and control, joint mobility, and patient understanding of the problem and how to manage it. Additional interventions like tape or manual treatment can also be implemented but should not be exclusive~Surgery: ACL surgical reconstruction
Study NCT02500355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release via limited approaches
Description: Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
Study NCT02500355 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carpal Tunnel Release via standard approach
Description: Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
Study NCT02500355 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic Carpal Tunnel Release
Description: Carpal tunnel release under endoscope.
Study NCT02500355 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: endoscope or an arthroscopic device
Study NCT00973973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken orally once a day
Study NCT00973973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Immediate release (IR) tablets taken orally once a day
Study NCT00973973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix
Description: Immediate release (IR) tablets taken orally once a day
Study NCT01290250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice based beverage enriched in polyphenols
Description: 2 daily doses (250 ml each) during 3 months
Study NCT01290250 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice based beverage enriched in polyphenols
Description: 2 daily doses (250 ml each) during 3 months
Study NCT01716195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy followed by Response Adapted Chemoradiation
Description: All patients receive induction chemotherapy with 2 cycles of paclitaxel and carboplatin followed by response adapted, de-escalated chemoradiation. Patients with a complete or partial response will receive 54 Gy with concurrent paclitaxel and patients with stable disease will receive 60 Gy with concurrent paclitaxel.
Study NCT02869139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentholated lip moisturizer and ice popsicle
Description: Mentholated package of measures
Study NCT02869139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-mentholated lip moisturizer and ice popsicle
Description: Non-mentholated package of measures
Study NCT03607084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School Health Worker Program
Description: The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
Study NCT02421211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
Study NCT02421211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir (LDV)
Description: Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
Study NCT02421211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)
Description: Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
Study NCT01897389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
Study NCT01978275 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plexolong 100, pajunk, germany
Description: nonstimulating catheter
Study NCT01834300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised exercise training
Description: The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
Study NCT01897389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
Study NCT01897389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
Study NCT01897389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
Study NCT01897389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
Study NCT03140696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg Alone
Description: A chicken egg will be offered for 2 days
Study NCT03140696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg and ready to use supplementary food (RUSF)
Description: A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
Study NCT03140696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg and breast milk
Description: A chicken egg and breast milk will be offered for 2 days
Study NCT01834300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
Study NCT01109160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Dihydrate
Description: Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
Study NCT04599153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventriculoperitoneal shunt opening pressure setting
Description: The ventriculoperitoneal shunt (Strata®) opening pressure can be changed using a magnetic tool. The possible settings are 0.5, 1.0, 1.5, 2.0, 2.5 with a higher setting number corresponding to a higher opening pressure and less drainage through the shunt. All settings are used in routine clinical practice.
Study NCT03134573 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaferon, BAY86-5046)
Description: Solution for injection
Study NCT03134573 — intervention group
Intervention type: DEVICE
Intervention: Betaconnect auto-injector
Description: Auto-injector for application of Betaferon solution which automatically covers injection related data
Study NCT03134573 — intervention group
Intervention type: DEVICE
Intervention: myBETAapp
Description: Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
Study NCT02397499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-202
Study NCT02314429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing lactic acid (racemic mixture)
Study NCT02201576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~3. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)
Study NCT00419640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with RA lead in LAS position
Description: Pacemaker implantation with RA lead placed in low atrial septal position
Study NCT02201576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchanges and intravenous immunoglobulins
Description: 1. Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~2. four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~3. oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)
Study NCT03729440 — intervention group
Intervention type: BEHAVIORAL
Intervention: development of complications or not
Description: assessment of development of complications
Study NCT03061643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 40 mg/m2 IV every 2 weeks plus ADT
Study NCT03061643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen-Deprivation Therapy (ADT)
Description: docetaxel 40 mg/m2 IV every 2 weeks plus ADT
Study NCT02323815 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Small-Quantity Lipid-based nutrient supplement
Description: A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
Study NCT02323815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child's health and nutrition topics
Description: Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
Study NCT02323815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child's health and nutrition topics
Description: Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
Study NCT00419640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation with RA lead in RAA position
Description: Pacemaker implantation with RA lead placed in right atrial appendage position
Study NCT00471354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
Study NCT03917888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
Study NCT01481779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Administered by SC injection via a pen device.
Study NCT01481779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered by SC injection with a pen device.
Study NCT01481779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered by SC injection with a pen device.
Study NCT01481779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered by SC injection with a pen device.
Study NCT02875600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutri Drink
Description: To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
Study NCT01537796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person weight loss
Description: Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
Study NCT00419640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation with RA lead in RAA position
Description: Pacemaker implantation with RA lead placed in right atrial appendage position
Study NCT02785887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatrician review
Description: In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
Study NCT00604474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HiResolution Bionic Ear System (Cochlear Implant)
Description: Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)